

Global Antifibrotic Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GD3821E868C0EN.html>

Date: September 2026

Pages: 126

Price: US\$ 3,480.00 (Single User License)

ID: GD3821E868C0EN

Abstracts

According to our (Global Info Research) latest study, the global Antifibrotic Drug market size was valued at US\$ million in 2025 and is forecast to a readjusted size of US\$ million by 2032 with a CAGR of %during review period.

Antifibrotic drugs are medications specifically designed to inhibit or slow down the process of fibrosis. The two main antifibrotic agents used for IPF are pirfenidone and nintedanib. Pirfenidone works by inhibiting processes involved in fibrosis, including reducing the production of pro-inflammatory cytokines and inhibiting fibroblast proliferation and collagen synthesis. Nintedanib, on the other hand, targets multiple tyrosine kinases that are implicated in pathways leading to fibrosis, thereby interfering with the progression of lung scarring.

This report is a detailed and comprehensive analysis for global Antifibrotic Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Antifibrotic Drug market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Antifibrotic Drug market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Antifibrotic Drug market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Antifibrotic Drug market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Antifibrotic Drug

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Antifibrotic Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim, Roche, Accord Healthcare, Amneal Pharmaceuticals, Sandoz, Teva, ScieGen Pharmaceuticals, Apotex, Gyré Pharmaceuticals, Káwin, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Antifibrotic Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for

consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Nintedanib

Pirfenidone

Market segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Major players covered

Boehringer Ingelheim

Roche

Accord Healthcare

Amneal Pharmaceuticals

Sandoz

Teva

ScieGen Pharmaceuticals

Apotex

Gyre Pharmaceuticals

Kawin

Beacon Pharma

Eskayef Pharmaceuticals

CSPC Pharmaceutical Group

Qilu Pharmaceutical

Kelun Pharmaceutical

PuraCap

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Antifibrotic Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Antifibrotic Drug, with price, sales quantity, revenue, and global market share of Antifibrotic Drug from 2021 to 2026.

Chapter 3, the Antifibrotic Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Antifibrotic Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Antifibrotic Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Antifibrotic Drug.

Chapter 14 and 15, to describe Antifibrotic Drug sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Antifibrotic Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 Nintedanib

1.3.3 Pirfenidone

1.4 Market Analysis by Application

1.4.1 Overview: Global Antifibrotic Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.4.2 Hospital and Clinic

1.4.3 Retail Pharmacies

1.4.4 Other

1.5 Global Antifibrotic Drug Market Size & Forecast

1.5.1 Global Antifibrotic Drug Consumption Value (2021 & 2025 & 2032)

1.5.2 Global Antifibrotic Drug Sales Quantity (2021-2032)

1.5.3 Global Antifibrotic Drug Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 Boehringer Ingelheim

2.1.1 Boehringer Ingelheim Details

2.1.2 Boehringer Ingelheim Major Business

2.1.3 Boehringer Ingelheim Antifibrotic Drug Product and Services

2.1.4 Boehringer Ingelheim Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 Boehringer Ingelheim Recent Developments/Updates

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche Antifibrotic Drug Product and Services

2.2.4 Roche Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 Roche Recent Developments/Updates

2.3 Accord Healthcare

- 2.3.1 Accord Healthcare Details
- 2.3.2 Accord Healthcare Major Business
- 2.3.3 Accord Healthcare Antifibrotic Drug Product and Services
- 2.3.4 Accord Healthcare Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Accord Healthcare Recent Developments/Updates
- 2.4 Amneal Pharmaceuticals
 - 2.4.1 Amneal Pharmaceuticals Details
 - 2.4.2 Amneal Pharmaceuticals Major Business
 - 2.4.3 Amneal Pharmaceuticals Antifibrotic Drug Product and Services
 - 2.4.4 Amneal Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.4.5 Amneal Pharmaceuticals Recent Developments/Updates
- 2.5 Sandoz
 - 2.5.1 Sandoz Details
 - 2.5.2 Sandoz Major Business
 - 2.5.3 Sandoz Antifibrotic Drug Product and Services
 - 2.5.4 Sandoz Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.5.5 Sandoz Recent Developments/Updates
- 2.6 Teva
 - 2.6.1 Teva Details
 - 2.6.2 Teva Major Business
 - 2.6.3 Teva Antifibrotic Drug Product and Services
 - 2.6.4 Teva Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.6.5 Teva Recent Developments/Updates
- 2.7 ScieGen Pharmaceuticals
 - 2.7.1 ScieGen Pharmaceuticals Details
 - 2.7.2 ScieGen Pharmaceuticals Major Business
 - 2.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Product and Services
 - 2.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.7.5 ScieGen Pharmaceuticals Recent Developments/Updates
- 2.8 Apotex
 - 2.8.1 Apotex Details
 - 2.8.2 Apotex Major Business
 - 2.8.3 Apotex Antifibrotic Drug Product and Services
 - 2.8.4 Apotex Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin

and Market Share (2021-2026)

2.8.5 Apotex Recent Developments/Updates

2.9 Gyre Pharmaceuticals

2.9.1 Gyre Pharmaceuticals Details

2.9.2 Gyre Pharmaceuticals Major Business

2.9.3 Gyre Pharmaceuticals Antifibrotic Drug Product and Services

2.9.4 Gyre Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 Gyre Pharmaceuticals Recent Developments/Updates

2.10 Kawin

2.10.1 Kawin Details

2.10.2 Kawin Major Business

2.10.3 Kawin Antifibrotic Drug Product and Services

2.10.4 Kawin Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.10.5 Kawin Recent Developments/Updates

2.11 Beacon Pharma

2.11.1 Beacon Pharma Details

2.11.2 Beacon Pharma Major Business

2.11.3 Beacon Pharma Antifibrotic Drug Product and Services

2.11.4 Beacon Pharma Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 Beacon Pharma Recent Developments/Updates

2.12 Eskayef Pharmaceuticals

2.12.1 Eskayef Pharmaceuticals Details

2.12.2 Eskayef Pharmaceuticals Major Business

2.12.3 Eskayef Pharmaceuticals Antifibrotic Drug Product and Services

2.12.4 Eskayef Pharmaceuticals Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.12.5 Eskayef Pharmaceuticals Recent Developments/Updates

2.13 CSPC Pharmaceutical Group

2.13.1 CSPC Pharmaceutical Group Details

2.13.2 CSPC Pharmaceutical Group Major Business

2.13.3 CSPC Pharmaceutical Group Antifibrotic Drug Product and Services

2.13.4 CSPC Pharmaceutical Group Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.13.5 CSPC Pharmaceutical Group Recent Developments/Updates

2.14 Qilu Pharmaceutical

2.14.1 Qilu Pharmaceutical Details

- 2.14.2 Qilu Pharmaceutical Major Business
- 2.14.3 Qilu Pharmaceutical Antifibrotic Drug Product and Services
- 2.14.4 Qilu Pharmaceutical Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Qilu Pharmaceutical Recent Developments/Updates
- 2.15 Kelun Pharmaceutical
 - 2.15.1 Kelun Pharmaceutical Details
 - 2.15.2 Kelun Pharmaceutical Major Business
 - 2.15.3 Kelun Pharmaceutical Antifibrotic Drug Product and Services
 - 2.15.4 Kelun Pharmaceutical Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.15.5 Kelun Pharmaceutical Recent Developments/Updates
- 2.16 PuraCap
 - 2.16.1 PuraCap Details
 - 2.16.2 PuraCap Major Business
 - 2.16.3 PuraCap Antifibrotic Drug Product and Services
 - 2.16.4 PuraCap Antifibrotic Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.16.5 PuraCap Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: ANTIFIBROTIC DRUG BY MANUFACTURER

- 3.1 Global Antifibrotic Drug Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Antifibrotic Drug Revenue by Manufacturer (2021-2026)
- 3.3 Global Antifibrotic Drug Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
 - 3.4.1 Producer Shipments of Antifibrotic Drug by Manufacturer Revenue (\$MM) and Market Share (%): 2025
 - 3.4.2 Top 3 Antifibrotic Drug Manufacturer Market Share in 2025
 - 3.4.3 Top 6 Antifibrotic Drug Manufacturer Market Share in 2025
- 3.5 Antifibrotic Drug Market: Overall Company Footprint Analysis
 - 3.5.1 Antifibrotic Drug Market: Region Footprint
 - 3.5.2 Antifibrotic Drug Market: Company Product Type Footprint
 - 3.5.3 Antifibrotic Drug Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Antifibrotic Drug Market Size by Region

- 4.1.1 Global Antifibrotic Drug Sales Quantity by Region (2021-2032)
- 4.1.2 Global Antifibrotic Drug Consumption Value by Region (2021-2032)
- 4.1.3 Global Antifibrotic Drug Average Price by Region (2021-2032)

4.2 North America Antifibrotic Drug Consumption Value (2021-2032)

4.3 Europe Antifibrotic Drug Consumption Value (2021-2032)

4.4 Asia-Pacific Antifibrotic Drug Consumption Value (2021-2032)

4.5 South America Antifibrotic Drug Consumption Value (2021-2032)

4.6 Middle East & Africa Antifibrotic Drug Consumption Value (2021-2032)

5 MARKET SEGMENT BY TYPE

5.1 Global Antifibrotic Drug Sales Quantity by Type (2021-2032)

5.2 Global Antifibrotic Drug Consumption Value by Type (2021-2032)

5.3 Global Antifibrotic Drug Average Price by Type (2021-2032)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Antifibrotic Drug Sales Quantity by Application (2021-2032)

6.2 Global Antifibrotic Drug Consumption Value by Application (2021-2032)

6.3 Global Antifibrotic Drug Average Price by Application (2021-2032)

7 NORTH AMERICA

7.1 North America Antifibrotic Drug Sales Quantity by Type (2021-2032)

7.2 North America Antifibrotic Drug Sales Quantity by Application (2021-2032)

7.3 North America Antifibrotic Drug Market Size by Country

7.3.1 North America Antifibrotic Drug Sales Quantity by Country (2021-2032)

7.3.2 North America Antifibrotic Drug Consumption Value by Country (2021-2032)

7.3.3 United States Market Size and Forecast (2021-2032)

7.3.4 Canada Market Size and Forecast (2021-2032)

7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

8.1 Europe Antifibrotic Drug Sales Quantity by Type (2021-2032)

8.2 Europe Antifibrotic Drug Sales Quantity by Application (2021-2032)

8.3 Europe Antifibrotic Drug Market Size by Country

8.3.1 Europe Antifibrotic Drug Sales Quantity by Country (2021-2032)

8.3.2 Europe Antifibrotic Drug Consumption Value by Country (2021-2032)

8.3.3 Germany Market Size and Forecast (2021-2032)

8.3.4 France Market Size and Forecast (2021-2032)

8.3.5 United Kingdom Market Size and Forecast (2021-2032)

8.3.6 Russia Market Size and Forecast (2021-2032)

8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

9.1 Asia-Pacific Antifibrotic Drug Sales Quantity by Type (2021-2032)

9.2 Asia-Pacific Antifibrotic Drug Sales Quantity by Application (2021-2032)

9.3 Asia-Pacific Antifibrotic Drug Market Size by Region

9.3.1 Asia-Pacific Antifibrotic Drug Sales Quantity by Region (2021-2032)

9.3.2 Asia-Pacific Antifibrotic Drug Consumption Value by Region (2021-2032)

9.3.3 China Market Size and Forecast (2021-2032)

9.3.4 Japan Market Size and Forecast (2021-2032)

9.3.5 South Korea Market Size and Forecast (2021-2032)

9.3.6 India Market Size and Forecast (2021-2032)

9.3.7 Southeast Asia Market Size and Forecast (2021-2032)

9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

10.1 South America Antifibrotic Drug Sales Quantity by Type (2021-2032)

10.2 South America Antifibrotic Drug Sales Quantity by Application (2021-2032)

10.3 South America Antifibrotic Drug Market Size by Country

10.3.1 South America Antifibrotic Drug Sales Quantity by Country (2021-2032)

10.3.2 South America Antifibrotic Drug Consumption Value by Country (2021-2032)

10.3.3 Brazil Market Size and Forecast (2021-2032)

10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Antifibrotic Drug Sales Quantity by Type (2021-2032)

11.2 Middle East & Africa Antifibrotic Drug Sales Quantity by Application (2021-2032)

11.3 Middle East & Africa Antifibrotic Drug Market Size by Country

11.3.1 Middle East & Africa Antifibrotic Drug Sales Quantity by Country (2021-2032)

11.3.2 Middle East & Africa Antifibrotic Drug Consumption Value by Country
(2021-2032)

11.3.3 Turkey Market Size and Forecast (2021-2032)

11.3.4 Egypt Market Size and Forecast (2021-2032)

11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)

11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

12.1 Antifibrotic Drug Market Drivers

12.2 Antifibrotic Drug Market Restraints

12.3 Antifibrotic Drug Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Antifibrotic Drug and Key Manufacturers

13.2 Manufacturing Costs Percentage of Antifibrotic Drug

13.3 Antifibrotic Drug Production Process

13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Antifibrotic Drug Typical Distributors

14.3 Antifibrotic Drug Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Antifibrotic Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Antifibrotic Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 3. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors

Table 4. Boehringer Ingelheim Major Business

Table 5. Boehringer Ingelheim Antifibrotic Drug Product and Services

Table 6. Boehringer Ingelheim Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 7. Boehringer Ingelheim Recent Developments/Updates

Table 8. Roche Basic Information, Manufacturing Base and Competitors

Table 9. Roche Major Business

Table 10. Roche Antifibrotic Drug Product and Services

Table 11. Roche Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 12. Roche Recent Developments/Updates

Table 13. Accord Healthcare Basic Information, Manufacturing Base and Competitors

Table 14. Accord Healthcare Major Business

Table 15. Accord Healthcare Antifibrotic Drug Product and Services

Table 16. Accord Healthcare Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 17. Accord Healthcare Recent Developments/Updates

Table 18. Amneal Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 19. Amneal Pharmaceuticals Major Business

Table 20. Amneal Pharmaceuticals Antifibrotic Drug Product and Services

Table 21. Amneal Pharmaceuticals Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 22. Amneal Pharmaceuticals Recent Developments/Updates

Table 23. Sandoz Basic Information, Manufacturing Base and Competitors

Table 24. Sandoz Major Business

Table 25. Sandoz Antifibrotic Drug Product and Services

Table 26. Sandoz Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 27. Sandoz Recent Developments/Updates

Table 28. Teva Basic Information, Manufacturing Base and Competitors

Table 29. Teva Major Business

Table 30. Teva Antifibrotic Drug Product and Services

Table 31. Teva Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 32. Teva Recent Developments/Updates

Table 33. ScieGen Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 34. ScieGen Pharmaceuticals Major Business

Table 35. ScieGen Pharmaceuticals Antifibrotic Drug Product and Services

Table 36. ScieGen Pharmaceuticals Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 37. ScieGen Pharmaceuticals Recent Developments/Updates

Table 38. Apotex Basic Information, Manufacturing Base and Competitors

Table 39. Apotex Major Business

Table 40. Apotex Antifibrotic Drug Product and Services

Table 41. Apotex Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 42. Apotex Recent Developments/Updates

Table 43. Gyre Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 44. Gyre Pharmaceuticals Major Business

Table 45. Gyre Pharmaceuticals Antifibrotic Drug Product and Services

Table 46. Gyre Pharmaceuticals Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 47. Gyre Pharmaceuticals Recent Developments/Updates

Table 48. Kawin Basic Information, Manufacturing Base and Competitors

Table 49. Kawin Major Business

Table 50. Kawin Antifibrotic Drug Product and Services

Table 51. Kawin Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 52. Kawin Recent Developments/Updates

Table 53. Beacon Pharma Basic Information, Manufacturing Base and Competitors

Table 54. Beacon Pharma Major Business

Table 55. Beacon Pharma Antifibrotic Drug Product and Services

Table 56. Beacon Pharma Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 57. Beacon Pharma Recent Developments/Updates

Table 58. Eskayef Pharmaceuticals Basic Information, Manufacturing Base and

Competitors

Table 59. Eskayef Pharmaceuticals Major Business

Table 60. Eskayef Pharmaceuticals Antifibrotic Drug Product and Services

Table 61. Eskayef Pharmaceuticals Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 62. Eskayef Pharmaceuticals Recent Developments/Updates

Table 63. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors

Table 64. CSPC Pharmaceutical Group Major Business

Table 65. CSPC Pharmaceutical Group Antifibrotic Drug Product and Services

Table 66. CSPC Pharmaceutical Group Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 67. CSPC Pharmaceutical Group Recent Developments/Updates

Table 68. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 69. Qilu Pharmaceutical Major Business

Table 70. Qilu Pharmaceutical Antifibrotic Drug Product and Services

Table 71. Qilu Pharmaceutical Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 72. Qilu Pharmaceutical Recent Developments/Updates

Table 73. Kelun Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 74. Kelun Pharmaceutical Major Business

Table 75. Kelun Pharmaceutical Antifibrotic Drug Product and Services

Table 76. Kelun Pharmaceutical Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 77. Kelun Pharmaceutical Recent Developments/Updates

Table 78. PuraCap Basic Information, Manufacturing Base and Competitors

Table 79. PuraCap Major Business

Table 80. PuraCap Antifibrotic Drug Product and Services

Table 81. PuraCap Antifibrotic Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 82. PuraCap Recent Developments/Updates

Table 83. Global Antifibrotic Drug Sales Quantity by Manufacturer (2021-2026) & (K Units)

Table 84. Global Antifibrotic Drug Revenue by Manufacturer (2021-2026) & (USD Million)

Table 85. Global Antifibrotic Drug Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 86. Market Position of Manufacturers in Antifibrotic Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 87. Head Office and Antifibrotic Drug Production Site of Key Manufacturer

Table 88. Antifibrotic Drug Market: Company Product Type Footprint

Table 89. Antifibrotic Drug Market: Company Product Application Footprint

Table 90. Antifibrotic Drug New Market Entrants and Barriers to Market Entry

Table 91. Antifibrotic Drug Mergers, Acquisition, Agreements, and Collaborations

Table 92. Global Antifibrotic Drug Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 93. Global Antifibrotic Drug Sales Quantity by Region (2021-2026) & (K Units)

Table 94. Global Antifibrotic Drug Sales Quantity by Region (2027-2032) & (K Units)

Table 95. Global Antifibrotic Drug Consumption Value by Region (2021-2026) & (USD Million)

Table 96. Global Antifibrotic Drug Consumption Value by Region (2027-2032) & (USD Million)

Table 97. Global Antifibrotic Drug Average Price by Region (2021-2026) & (US\$/Unit)

Table 98. Global Antifibrotic Drug Average Price by Region (2027-2032) & (US\$/Unit)

Table 99. Global Antifibrotic Drug Sales Quantity by Type (2021-2026) & (K Units)

Table 100. Global Antifibrotic Drug Sales Quantity by Type (2027-2032) & (K Units)

Table 101. Global Antifibrotic Drug Consumption Value by Type (2021-2026) & (USD Million)

Table 102. Global Antifibrotic Drug Consumption Value by Type (2027-2032) & (USD Million)

Table 103. Global Antifibrotic Drug Average Price by Type (2021-2026) & (US\$/Unit)

Table 104. Global Antifibrotic Drug Average Price by Type (2027-2032) & (US\$/Unit)

Table 105. Global Antifibrotic Drug Sales Quantity by Application (2021-2026) & (K Units)

Table 106. Global Antifibrotic Drug Sales Quantity by Application (2027-2032) & (K Units)

Table 107. Global Antifibrotic Drug Consumption Value by Application (2021-2026) & (USD Million)

Table 108. Global Antifibrotic Drug Consumption Value by Application (2027-2032) & (USD Million)

Table 109. Global Antifibrotic Drug Average Price by Application (2021-2026) & (US\$/Unit)

Table 110. Global Antifibrotic Drug Average Price by Application (2027-2032) & (US\$/Unit)

Table 111. North America Antifibrotic Drug Sales Quantity by Type (2021-2026) & (K Units)

Table 112. North America Antifibrotic Drug Sales Quantity by Type (2027-2032) & (K Units)

Table 113. North America Antifibrotic Drug Sales Quantity by Application (2021-2026) & (K Units)

Table 114. North America Antifibrotic Drug Sales Quantity by Application (2027-2032) & (K Units)

Table 115. North America Antifibrotic Drug Sales Quantity by Country (2021-2026) & (K Units)

Table 116. North America Antifibrotic Drug Sales Quantity by Country (2027-2032) & (K Units)

Table 117. North America Antifibrotic Drug Consumption Value by Country (2021-2026) & (USD Million)

Table 118. North America Antifibrotic Drug Consumption Value by Country (2027-2032) & (USD Million)

Table 119. Europe Antifibrotic Drug Sales Quantity by Type (2021-2026) & (K Units)

Table 120. Europe Antifibrotic Drug Sales Quantity by Type (2027-2032) & (K Units)

Table 121. Europe Antifibrotic Drug Sales Quantity by Application (2021-2026) & (K Units)

Table 122. Europe Antifibrotic Drug Sales Quantity by Application (2027-2032) & (K Units)

Table 123. Europe Antifibrotic Drug Sales Quantity by Country (2021-2026) & (K Units)

Table 124. Europe Antifibrotic Drug Sales Quantity by Country (2027-2032) & (K Units)

Table 125. Europe Antifibrotic Drug Consumption Value by Country (2021-2026) & (USD Million)

Table 126. Europe Antifibrotic Drug Consumption Value by Country (2027-2032) & (USD Million)

Table 127. Asia-Pacific Antifibrotic Drug Sales Quantity by Type (2021-2026) & (K Units)

Table 128. Asia-Pacific Antifibrotic Drug Sales Quantity by Type (2027-2032) & (K Units)

Table 129. Asia-Pacific Antifibrotic Drug Sales Quantity by Application (2021-2026) & (K Units)

Table 130. Asia-Pacific Antifibrotic Drug Sales Quantity by Application (2027-2032) & (K Units)

Table 131. Asia-Pacific Antifibrotic Drug Sales Quantity by Region (2021-2026) & (K Units)

Table 132. Asia-Pacific Antifibrotic Drug Sales Quantity by Region (2027-2032) & (K Units)

Table 133. Asia-Pacific Antifibrotic Drug Consumption Value by Region (2021-2026) &

(USD Million)

Table 134. Asia-Pacific Antifibrotic Drug Consumption Value by Region (2027-2032) & (USD Million)

Table 135. South America Antifibrotic Drug Sales Quantity by Type (2021-2026) & (K Units)

Table 136. South America Antifibrotic Drug Sales Quantity by Type (2027-2032) & (K Units)

Table 137. South America Antifibrotic Drug Sales Quantity by Application (2021-2026) & (K Units)

Table 138. South America Antifibrotic Drug Sales Quantity by Application (2027-2032) & (K Units)

Table 139. South America Antifibrotic Drug Sales Quantity by Country (2021-2026) & (K Units)

Table 140. South America Antifibrotic Drug Sales Quantity by Country (2027-2032) & (K Units)

Table 141. South America Antifibrotic Drug Consumption Value by Country (2021-2026) & (USD Million)

Table 142. South America Antifibrotic Drug Consumption Value by Country (2027-2032) & (USD Million)

Table 143. Middle East & Africa Antifibrotic Drug Sales Quantity by Type (2021-2026) & (K Units)

Table 144. Middle East & Africa Antifibrotic Drug Sales Quantity by Type (2027-2032) & (K Units)

Table 145. Middle East & Africa Antifibrotic Drug Sales Quantity by Application (2021-2026) & (K Units)

Table 146. Middle East & Africa Antifibrotic Drug Sales Quantity by Application (2027-2032) & (K Units)

Table 147. Middle East & Africa Antifibrotic Drug Sales Quantity by Country (2021-2026) & (K Units)

Table 148. Middle East & Africa Antifibrotic Drug Sales Quantity by Country (2027-2032) & (K Units)

Table 149. Middle East & Africa Antifibrotic Drug Consumption Value by Country (2021-2026) & (USD Million)

Table 150. Middle East & Africa Antifibrotic Drug Consumption Value by Country (2027-2032) & (USD Million)

Table 151. Antifibrotic Drug Raw Material

Table 152. Key Manufacturers of Antifibrotic Drug Raw Materials

Table 153. Antifibrotic Drug Typical Distributors

Table 154. Antifibrotic Drug Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Antifibrotic Drug Picture

Figure 2. Global Antifibrotic Drug Revenue by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global Antifibrotic Drug Revenue Market Share by Type in 2025

Figure 4. Nintedanib Examples

Figure 5. Pirfenidone Examples

Figure 6. Global Antifibrotic Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 7. Global Antifibrotic Drug Revenue Market Share by Application in 2025

Figure 8. Hospital and Clinic Examples

Figure 9. Retail Pharmacies Examples

Figure 10. Other Examples

Figure 11. Global Antifibrotic Drug Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 12. Global Antifibrotic Drug Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 13. Global Antifibrotic Drug Sales Quantity (2021-2032) & (K Units)

Figure 14. Global Antifibrotic Drug Price (2021-2032) & (US\$/Unit)

Figure 15. Global Antifibrotic Drug Sales Quantity Market Share by Manufacturer in 2025

Figure 16. Global Antifibrotic Drug Revenue Market Share by Manufacturer in 2025

Figure 17. Producer Shipments of Antifibrotic Drug by Manufacturer Sales (\$MM) and Market Share (%): 2025

Figure 18. Top 3 Antifibrotic Drug Manufacturer (Revenue) Market Share in 2025

Figure 19. Top 6 Antifibrotic Drug Manufacturer (Revenue) Market Share in 2025

Figure 20. Global Antifibrotic Drug Sales Quantity Market Share by Region (2021-2032)

Figure 21. Global Antifibrotic Drug Consumption Value Market Share by Region (2021-2032)

Figure 22. North America Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 23. Europe Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 24. Asia-Pacific Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 25. South America Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 26. Middle East & Africa Antifibrotic Drug Consumption Value (2021-2032) &

(USD Million)

Figure 27. Global Antifibrotic Drug Sales Quantity Market Share by Type (2021-2032)

Figure 28. Global Antifibrotic Drug Consumption Value Market Share by Type
(2021-2032)

Figure 29. Global Antifibrotic Drug Average Price by Type (2021-2032) & (US\$/Unit)

Figure 30. Global Antifibrotic Drug Sales Quantity Market Share by Application
(2021-2032)

Figure 31. Global Antifibrotic Drug Revenue Market Share by Application (2021-2032)

Figure 32. Global Antifibrotic Drug Average Price by Application (2021-2032) &
(US\$/Unit)

Figure 33. North America Antifibrotic Drug Sales Quantity Market Share by Type
(2021-2032)

Figure 34. North America Antifibrotic Drug Sales Quantity Market Share by Application
(2021-2032)

Figure 35. North America Antifibrotic Drug Sales Quantity Market Share by Country
(2021-2032)

Figure 36. North America Antifibrotic Drug Consumption Value Market Share by Country
(2021-2032)

Figure 37. United States Antifibrotic Drug Consumption Value (2021-2032) & (USD
Million)

Figure 38. Canada Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 39. Mexico Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 40. Europe Antifibrotic Drug Sales Quantity Market Share by Type (2021-2032)

Figure 41. Europe Antifibrotic Drug Sales Quantity Market Share by Application
(2021-2032)

Figure 42. Europe Antifibrotic Drug Sales Quantity Market Share by Country
(2021-2032)

Figure 43. Europe Antifibrotic Drug Consumption Value Market Share by Country
(2021-2032)

Figure 44. Germany Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 45. France Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 46. United Kingdom Antifibrotic Drug Consumption Value (2021-2032) & (USD
Million)

Figure 47. Russia Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 48. Italy Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 49. Asia-Pacific Antifibrotic Drug Sales Quantity Market Share by Type
(2021-2032)

Figure 50. Asia-Pacific Antifibrotic Drug Sales Quantity Market Share by Application
(2021-2032)

Figure 51. Asia-Pacific Antifibrotic Drug Sales Quantity Market Share by Region (2021-2032)

Figure 52. Asia-Pacific Antifibrotic Drug Consumption Value Market Share by Region (2021-2032)

Figure 53. China Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 54. Japan Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 55. South Korea Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 56. India Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 57. Southeast Asia Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 58. Australia Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 59. South America Antifibrotic Drug Sales Quantity Market Share by Type (2021-2032)

Figure 60. South America Antifibrotic Drug Sales Quantity Market Share by Application (2021-2032)

Figure 61. South America Antifibrotic Drug Sales Quantity Market Share by Country (2021-2032)

Figure 62. South America Antifibrotic Drug Consumption Value Market Share by Country (2021-2032)

Figure 63. Brazil Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 64. Argentina Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 65. Middle East & Africa Antifibrotic Drug Sales Quantity Market Share by Type (2021-2032)

Figure 66. Middle East & Africa Antifibrotic Drug Sales Quantity Market Share by Application (2021-2032)

Figure 67. Middle East & Africa Antifibrotic Drug Sales Quantity Market Share by Country (2021-2032)

Figure 68. Middle East & Africa Antifibrotic Drug Consumption Value Market Share by Country (2021-2032)

Figure 69. Turkey Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 70. Egypt Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 71. Saudi Arabia Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 72. South Africa Antifibrotic Drug Consumption Value (2021-2032) & (USD Million)

Figure 73. Antifibrotic Drug Market Drivers

Figure 74. Antifibrotic Drug Market Restraints

Figure 75. Antifibrotic Drug Market Trends

Figure 76. Porters Five Forces Analysis

Figure 77. Manufacturing Cost Structure Analysis of Antifibrotic Drug in 2025

Figure 78. Manufacturing Process Analysis of Antifibrotic Drug

Figure 79. Antifibrotic Drug Industrial Chain

Figure 80. Sales Channel: Direct to End-User vs Distributors

Figure 81. Direct Channel Pros & Cons

Figure 82. Indirect Channel Pros & Cons

Figure 83. Methodology

Figure 84. Research Process and Data Source

I would like to order

Product name: Global Antifibrotic Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GD3821E868C0EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD3821E868C0EN.html>